vs
Side-by-side financial comparison of Astrana Health, Inc. (ASTH) and HAEMONETICS CORP (HAE). Click either name above to swap in a different company.
Astrana Health, Inc. is the larger business by last-quarter revenue ($950.5M vs $346.4M, roughly 2.7× HAEMONETICS CORP). HAEMONETICS CORP runs the higher net margin — 28.1% vs 0.7%, a 27.4% gap on every dollar of revenue. On growth, Astrana Health, Inc. posted the faster year-over-year revenue change (42.9% vs 4.8%). HAEMONETICS CORP produced more free cash flow last quarter ($209.9M vs $-6.0M). Over the past eight quarters, Astrana Health, Inc.'s revenue compounded faster (53.3% CAGR vs 1.5%).
Astrana Health, Inc. is a U.S.-based value-based healthcare services provider that primarily serves Medicare-eligible senior populations across the United States. It offers in-home primary care, chronic disease management, and care coordination services, aiming to improve patient health outcomes and reduce unnecessary medical costs.
Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen (Jack) Latham in the 1970s.
ASTH vs HAE — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2026
| Metric | | |
|---|---|---|
| Revenue | $950.5M | $346.4M |
| Net Profit | $6.6M | $97.3M |
| Gross Margin | — | 57.2% |
| Operating Margin | 1.9% | 36.1% |
| Net Margin | 0.7% | 28.1% |
| Revenue YoY | 42.9% | 4.8% |
| Net Profit YoY | 184.4% | — |
| EPS (diluted) | $0.12 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $346.4M | ||
| Q4 25 | $950.5M | $339.0M | ||
| Q3 25 | $956.0M | $327.3M | ||
| Q2 25 | $654.8M | $321.4M | ||
| Q1 25 | $620.4M | $330.6M | ||
| Q4 24 | $665.2M | $348.5M | ||
| Q3 24 | $478.7M | $345.5M | ||
| Q2 24 | $486.3M | $336.2M |
| Q1 26 | — | $97.3M | ||
| Q4 25 | $6.6M | $44.7M | ||
| Q3 25 | $373.0K | $38.7M | ||
| Q2 25 | $9.4M | $34.0M | ||
| Q1 25 | $6.7M | $58.0M | ||
| Q4 24 | $-7.8M | $37.5M | ||
| Q3 24 | $16.1M | $33.8M | ||
| Q2 24 | $19.2M | $38.4M |
| Q1 26 | — | 57.2% | ||
| Q4 25 | — | 59.7% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 59.8% | ||
| Q1 25 | — | 58.4% | ||
| Q4 24 | — | 55.5% | ||
| Q3 24 | — | 54.2% | ||
| Q2 24 | — | 52.0% |
| Q1 26 | — | 36.1% | ||
| Q4 25 | 1.9% | 19.9% | ||
| Q3 25 | 2.0% | 17.9% | ||
| Q2 25 | 3.1% | 16.8% | ||
| Q1 25 | 3.3% | 21.6% | ||
| Q4 24 | 0.1% | 16.9% | ||
| Q3 24 | 5.9% | 15.0% | ||
| Q2 24 | 6.2% | 11.8% |
| Q1 26 | — | 28.1% | ||
| Q4 25 | 0.7% | 13.2% | ||
| Q3 25 | 0.0% | 11.8% | ||
| Q2 25 | 1.4% | 10.6% | ||
| Q1 25 | 1.1% | 17.5% | ||
| Q4 24 | -1.2% | 10.8% | ||
| Q3 24 | 3.4% | 9.8% | ||
| Q2 24 | 3.9% | 11.4% |
| Q1 26 | — | — | ||
| Q4 25 | $0.12 | $0.95 | ||
| Q3 25 | $0.01 | $0.81 | ||
| Q2 25 | $0.19 | $0.70 | ||
| Q1 25 | $0.14 | $1.17 | ||
| Q4 24 | $-0.14 | $0.74 | ||
| Q3 24 | $0.33 | $0.66 | ||
| Q2 24 | $0.40 | $0.74 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $429.5M | $245.4M |
| Total DebtLower is stronger | — | $1.2B |
| Stockholders' EquityBook value | $779.3M | $796.3M |
| Total Assets | $2.2B | $2.4B |
| Debt / EquityLower = less leverage | — | 1.53× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $245.4M | ||
| Q4 25 | $429.5M | $363.4M | ||
| Q3 25 | $463.4M | $296.4M | ||
| Q2 25 | $342.1M | $292.9M | ||
| Q1 25 | $260.9M | $306.8M | ||
| Q4 24 | $290.8M | $320.8M | ||
| Q3 24 | $350.3M | $299.3M | ||
| Q2 24 | $327.7M | $344.4M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | — | $1.2B | ||
| Q3 25 | — | $1.2B | ||
| Q2 25 | — | $1.2B | ||
| Q1 25 | — | $1.2B | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $796.3M | ||
| Q4 25 | $779.3M | $911.5M | ||
| Q3 25 | $775.5M | $849.2M | ||
| Q2 25 | $765.5M | $882.3M | ||
| Q1 25 | $745.4M | $820.8M | ||
| Q4 24 | $712.7M | $906.9M | ||
| Q3 24 | $704.6M | $878.9M | ||
| Q2 24 | $678.9M | $905.4M |
| Q1 26 | — | $2.4B | ||
| Q4 25 | $2.2B | $2.5B | ||
| Q3 25 | $2.2B | $2.4B | ||
| Q2 25 | $1.4B | $2.5B | ||
| Q1 25 | $1.3B | $2.5B | ||
| Q4 24 | $1.4B | $2.5B | ||
| Q3 24 | $1.3B | $2.5B | ||
| Q2 24 | $1.3B | $2.5B |
| Q1 26 | — | 1.53× | ||
| Q4 25 | — | 1.34× | ||
| Q3 25 | — | 1.44× | ||
| Q2 25 | — | 1.39× | ||
| Q1 25 | — | 1.49× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-2.9M | $293.2M |
| Free Cash FlowOCF − Capex | $-6.0M | $209.9M |
| FCF MarginFCF / Revenue | -0.6% | 60.6% |
| Capex IntensityCapex / Revenue | 0.3% | 9.5% |
| Cash ConversionOCF / Net Profit | -0.44× | 3.01× |
| TTM Free Cash FlowTrailing 4 quarters | $104.5M | $417.1M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $293.2M | ||
| Q4 25 | $-2.9M | $93.6M | ||
| Q3 25 | $10.0M | $111.3M | ||
| Q2 25 | $90.9M | $17.4M | ||
| Q1 25 | $16.6M | $116.6M | ||
| Q4 24 | $-10.9M | $43.8M | ||
| Q3 24 | $34.0M | $48.8M | ||
| Q2 24 | $23.2M | $-27.4M |
| Q1 26 | — | $209.9M | ||
| Q4 25 | $-6.0M | $87.2M | ||
| Q3 25 | $7.4M | $106.3M | ||
| Q2 25 | $89.5M | $13.6M | ||
| Q1 25 | $13.6M | $100.9M | ||
| Q4 24 | $-13.5M | $35.2M | ||
| Q3 24 | $31.7M | $39.4M | ||
| Q2 24 | $20.4M | $-33.1M |
| Q1 26 | — | 60.6% | ||
| Q4 25 | -0.6% | 25.7% | ||
| Q3 25 | 0.8% | 32.5% | ||
| Q2 25 | 13.7% | 4.2% | ||
| Q1 25 | 2.2% | 30.5% | ||
| Q4 24 | -2.0% | 10.1% | ||
| Q3 24 | 6.6% | 11.4% | ||
| Q2 24 | 4.2% | -9.8% |
| Q1 26 | — | 9.5% | ||
| Q4 25 | 0.3% | 1.9% | ||
| Q3 25 | 0.3% | 1.5% | ||
| Q2 25 | 0.2% | 1.2% | ||
| Q1 25 | 0.5% | 4.7% | ||
| Q4 24 | 0.4% | 2.5% | ||
| Q3 24 | 0.5% | 2.7% | ||
| Q2 24 | 0.6% | 1.7% |
| Q1 26 | — | 3.01× | ||
| Q4 25 | -0.44× | 2.09× | ||
| Q3 25 | 26.69× | 2.88× | ||
| Q2 25 | 9.65× | 0.51× | ||
| Q1 25 | 2.48× | 2.01× | ||
| Q4 24 | — | 1.17× | ||
| Q3 24 | 2.11× | 1.44× | ||
| Q2 24 | 1.21× | -0.71× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ASTH
| Medicare | $542.4M | 57% |
| Commercial | $99.1M | 10% |
| Care Delivery | $92.1M | 10% |
| Care Enablement | $78.9M | 8% |
| Other Third Parties | $58.0M | 6% |
| Health Care Patient Service | $39.8M | 4% |
| Health Care Other | $25.5M | 3% |
| Other | $12.1M | 1% |
| Management Service | $10.3M | 1% |
HAE
| Hospital | $159.6M | 46% |
| Plasma | $130.3M | 38% |
| Blood Center | $56.4M | 16% |
